Management of multidrug-resistant tuberculosis and patients in retreatment

European Respiratory Journal

Volumn 25, Issue 5, 2005, Pages 928-936

  Caminero, J A ^a  

^a HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

Author keywords

Multidrug resistant tuberculosis; Standardised regimen; Treatment; Tuberculosis management

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; CAPREOMYCIN; CIPROFLOXACIN; CLOFAZIMINE; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; RIFAMPICIN; SPARFLOXACIN; STREPTOMYCIN; THIOACETAZONE; TUBERCULOSTATIC AGENT;

ARTICLE; CLINICAL PROTOCOL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG RESPONSE; DRUG SENSITIVITY; FINANCIAL MANAGEMENT; HEALTH CARE COST; HUMAN; LUNG TUBERCULOSIS; MICROBIOLOGICAL EXAMINATION; MULTIDRUG RESISTANCE; PATIENT MONITORING; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; RELIABILITY; STANDARDIZATION; TREATMENT PLANNING;

ANTIBIOTICS, ANTITUBERCULAR; CLINICAL PROTOCOLS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; MEDICAL HISTORY TAKING; RECURRENCE; TREATMENT FAILURE; TREATMENT REFUSAL; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 18744388051     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.05.00103004     Document Type: Article

References (57)

1. Caminero JA. Guía de la Tuberculosis para Médicos Especialistas. [Tuberculosis Guide for Specialist Physicians]. Paris, International Union Against Tuberculosis and Lung Disease, 2003.
2. Espinal MA, Laszlo A, Simonsen L, et al. Global trends in resistance to antituberculosis drugs. N Engl J Med 2001; 344: 1294-1303.
3. Espinal MA, Kim SJ, Suarez PG, et al. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. JAMA 2000; 283: 2537-2545.
4. Partners in Health, Program in Infectious Disease and Social Change, Harvard Medical School. The PIH Guide to the Medical Management of Multidrug-Resistant Tuberculosis. Boston, MA, Partners in Health, 2003.
5. World Health Organization. Treatment of Tuberculosis. Guidelines for National Programmes. 3rd Edn. Geneva, World Health Organization, 2003.
6. Mitchison DA. Basic mechanisms of chemotherapy. Chest 1979; 76: 771-781.
7. Caminero JA, Pena MJ, Campos-Herrero MI, et al. Exogenous reinfection with tuberculosis on a European island with a moderate incidence of disease. Am J Respir Crit Care Med 2001; 163: 717-720.
8. van Rie A, Warren R, Richardson M, et al. Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment. N Engl J Med 1999; 341: 1174-1179.
9. Valenzuela P, Piffardi S, Lepe R, Velasco M. Panorama actualizado de la resistencia a fármacos antituberculosos. Chile - 1998. [Updated situation of antituberculous drug resistance. Chile - 1998]. Rev Chil Infect 1998; 15: 225-233.
10. Enarson DA, Rieder HL, Arnadottir T, Trébucq A. Management of Tuberculosis. A Guide for Low Income Countries. 5th Edn. Paris, International Union Against Tuberculosis and Lung Disease, 2000.
11. Tuberculosis Research Centre, Indian Council of Medical Research. Low rate of emergence of drug resistance in sputum positive patients treated with short course chemotherapy. Int J Tuberc Lung Dis 2001; 5: 40-45.
12. Mitchison DA. How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis. Int J Tuberc Lung Dis 1998; 2: 10-15.
13. American Thoracic Society. Chemotherapy of pulmonary tuberculosis in adults: The choice of drugs in relation to drug susceptibility. Am Rev Respir Dis 1965; 92: 508-512.
14. American Thoracic Society. Treatment of drug-resistant tuberculosis. Am Rev Respir Dis 1966; 94: 125-127.
15. Iseman MD. Treatment of multidrug-resistant tuberculosis. N Engl J Med 1993; 329: 784-791.
16. Ortega A. Retratamientos en tuberculosis. [Retreatment in tuberculosis]. Rev Clin Esp 1987; 180: 269-274.
17. Caminero JA. Data not published.
18. Kim SJ. Drug-susceptibility testing in tuberculosis: methods and reliability of the results. Eur Respir J 2005; 25: 564-569.
19. Canetti G. Present aspects of bacterial resistance in tuberculosis. Am Rev Respir Dis 1965; 92: 687-703.
20. AmericanThoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America. Treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167: 603-662.
21. Goble M, Iseman MD, Madsen LA, Waite D, Ackerson L, Horsburgh R. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med 1993; 328: 527-532.
22. Park SK, Kim CT, Song SD. Outcome of chemotherapy in 107 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. Int J Tuberc Lung Dis 1998; 2: 877-884.
23. Geerligs WA, Altena R, de Lange WCM, van Soolingen D, van der Werf TS. Multidrug-resistant tuberculosis: long-term treatment outcome in the Netherlands. Int J Tuberc Lung Dis 2000; 4: 758-764.
24. Caminero JA, March P. Statements of ATS, CDC, and IDSA on treatment of tuberculosis. Am J Respir Crit Care Med 2004; 169: 316-317.
25. British Tuberculosis Association. A Report from the Research Committee of the British Tuberculosis Association. Ethionamide, pyrazinamide and cycloserine in the treatment of drug-resistant pulmonary tuberculosis. Tubercle 1963; 44: 195-214.
26. Jancik E, Zelenka M, Tousek, Makova M. Chemotherapy for patients with cultures resistant to streptmomycin, isoniazid and PAS. Tubercle 1963; 44: 443-445.
27. de March P, Burell J. Resultados obtenidos mediante regimees de asociación con dos o tres drogas secundarias en el retratamiento del tuberculoso pulmonar crónico. [Results obtained with regimes with two or three second-line drugs in the retreatment of patients with chronic tuberculosis]. Rev Clin Esp 1968; 109: 119-126.
28. Kass I. Chemotherapy regimes used in retreament of pulmonary tuberculosis. Part II. Observations on the efficacy of combinations of kanamycin, ethionamide and either cycloserine or pyrazinamide. Tubercle 1965; 46: 151-165.
29. Kass I. Chemotherapy regimes used in retreatment of pulmonary tuberculosis. Part I. Observations on the efficacy of ethambutol, capreomycin and companion drugs, including 4-4 diisoamyloxy-thiosemicarbanilide. Tubercle 1965; 46: 166-77.
30. Tousek J, Jancik E, Zelenca M, Jancikova-Makova, M. The results of treatment in patients with cultures resistant to streptomycin, isoniazid and PAS: a five-year follow-up. Tubercle 1967; 48: 27-32.
31. Fischer DA, Lester W, Dye WE, Moulding TS. Retreatment of patients with isoniazid-resistant tuberculosis: analysis and follow-up of 146 cases. Am Rev Respir Dis 1968; 97: 392-398.
32. American Thoracic Society. Treatment of tuberculosis and tuberculosis infection in adults and children. Am J Respir Crit Care Med 1994; 149: 1359-1374.
33. Lester W, Fischer DA, Moulding T. Chemotherapy results in 257 consecutively studied cases of drug resistant tuberculosis. Am Rev Respir Dis 1967; 96: 142.
34. Lester W, Fischer DA, Dye WE. Evaluation of capreomycin and ethambutol in retreatment of pulmonary tuberculosis. Ann N Y Acad Sci 1966; 135: 890-903.
35. Pines A. Treatment of pulmonary tuberculosis with cultures resistant to two or more drugs: a series of 44 patients. Tubercle 1965; 46: 131-142.
36. Somner AR, Brace AA. Late results of treatment of chronic resistant pulmonary tuberculosis. BMJ 1966; 1: 775-778.
37. Sommer AR, Brace AA. Ethionamide, pyrazinamide and cycloserine used successfully in the treatment of chronic pulmonary tuberculosis. Tubercle 1962; 43: 345-359.
38. East African/British Medical Research Council. Streptomycin plus PAS plus pyrazinamide in the treatment of pulmonary tuberculosis in East Africa. Tubercle 1971; 52: 191-198.
39. East African/British Medical Research Council. Streptomycin plus PAS plus pyrazinamide in the treatment of pulmonary tuberculosis in East Africa: second report. Tubercle 1973; 54: 283-290.
40. Zierski M. Treatment of patients with culture resistant to the primary antituberculous drugs. Tubercle 1964; 45: 96-100.
41. Doust JY, Moatamed F. Retreatment program in pulmonary tuberculosis with resistant mycobacteria in South of Iran. Dis Chest 1967; 52: 21-25.
42. Giunio N. Chemotherapy of previously treated patients with pulmonary tuberculosis. Tubercle 1964; 45: 202-204.
43. Telzak EE, Sepkowitz K, Alpert P, et al. Multidrug-resistant tuberculosis in patients without HIV infection. N Engl J Med 1995; 333: 907-911.
44. Narita M, Alonso P, Lauzardo M, Hollender ES, Pitchennik AE, Ashkin D. Treatment experience of multidrug-resistant tuberculosis in Florida, 1994-1997. Chest 2001; 120: 343-348.
45. Tahaoglu K, Torun T, Sevim T, et al. The treatment of multidrug-resistant tuberculosis in Turkey. N Engl J Med 2001; 345: 170-174.
46. Avendano M, Goldstein RS. Multidrug-resistant tuberculosis: long term follow-up of 40 non-HIV-infected patients. Can Respir J 2000; 7: 383-389.
47. Yew WW, Chan CK, Chau CH, et al. Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimes. Chest 2000; 117: 744-751.
48. Kim HJ, Hong YP, Kim SJ, Lew WJ, Lee EG. Ambulatory treatment of multidrug-resistant pulmonary tuberculosis patients: at a chest clinic. Int J Tuberc Lung Dis 2001; 5: 1129-1136.
49. Mitnick C, Bayona J, Palacios E, et al. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med 2003; 348: 119-128.
50. Programa Nacional de Control de la Tuberculosis. Situación de la tuberculosis en El Salvador, 2001. [National Tuberculosis Control Programme. Tuberculosis Situation in El Salvador, 2001]. San Salvador, Ministry of Public Health, Republic of El Salvador, 2002.
51. Programa Nacional de Control de la Tuberculosis. Situación de la tuberculosis en República Dominicana, 2002. [National Tuberculosis Control Programme. Tuberculosis Situation in Dominican Republic, 2002]. Santo Domingo, Ministry of Public Health, Dominican Republic, 2003.
52. Programa Nacional de Control de la Tuberculosis. Situación y control de la tuberculosis en Bolivia, 1999-2000. [National Tuberculosis Control Programme. Tuberculosis Situation and Control in Bolivia, 1999-2000]. La Paz, Ministry of Public Health, Republic of Bolivia, 2001.
53. Programa Nacional de Control de la Tuberculosis. Situación de la Tuberculosis en Honduras y estrategias de control. [National Tuberculosis Control Programme. Tuberculosis Situation and Control Strategies in Honduras]. Tegucigalpa, Ministry of Public Health, Republic of Honduras, 2002.
54. (E.A. Nardell, Division of Medicine, Harvard Medical School, Cambridge Hospital, Cambridge, MA, USA; personal communication).
55. Suarez PG, Floyd K, Portocarrero J, et al. Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru. Lancet 2002; 359: 1980-1989.
56. (K. Weyer, National Tuberculosis Research Programme, Medical Research Council, Pretoria, South Africa; personal communication).
57. Personal communication from the Group on DOTS-Plus for MDR-TB. 34th IUATLD World Conference on Lung Health, Paris, 2003.